AbCellera Biologics Inc. Increase (Decrease) in Receivables
AbCellera Biologics Inc. (ABCL) reported Increase (Decrease) in Receivables of -$13.10 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivables · last filed 2026-05-11
- AbCellera Biologics Inc. increase (decrease) in receivables for the quarter ending 2026-03-31 was -$13.10M, a 1256.49% decline year-over-year.
- AbCellera Biologics Inc. increase (decrease) in receivables for the quarter ending 2025-12-31 was $39.67M, a 90.14% increase year-over-year.
- AbCellera Biologics Inc. increase (decrease) in receivables for the quarter ending 2025-09-30 was $3.43M, a 82.68% decline year-over-year.
- AbCellera Biologics Inc. increase (decrease) in receivables for the quarter ending 2025-06-30 was $11.39M, a 28.17% decline year-over-year.
- AbCellera Biologics Inc. increase (decrease) in receivables for fiscal 2025 was $55.62M, a 25.95% decline from fiscal 2024.
- AbCellera Biologics Inc. increase (decrease) in receivables for fiscal 2024 was $75.12M, a 63.54% increase from fiscal 2023.
- AbCellera Biologics Inc. increase (decrease) in receivables for fiscal 2023 was $45.93M, a 102.21% increase from fiscal 2022.
- AbCellera Biologics Inc. increase (decrease) in receivables for fiscal 2022 was $22.71M, a 39.24% decline from fiscal 2021.
| Period end | Increase (Decrease) in Receivables 3 month | Increase (Decrease) in Receivables 6 month | Increase (Decrease) in Receivables 9 month | Increase (Decrease) in Receivables 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$13.10M 10-Q · filed 2026-05-11 | $26.56M derived: sum of 2 quarters · filed 2026-05-11 | $30.00M derived: sum of 3 quarters · filed 2026-05-11 | $41.39M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | $39.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $43.10M derived: sum of 2 quarters · filed 2026-02-24 | $54.49M derived: sum of 3 quarters · filed 2026-02-24 | $55.62M 10-K · filed 2026-02-24 |
| 2025-09-30 | $3.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $14.82M derived: sum of 2 quarters · filed 2025-11-06 | $15.96M 10-Q · filed 2025-11-06 | $36.82M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-06-30 | $11.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $12.52M 10-Q · filed 2025-08-07 | $33.38M derived: sum of 3 quarters · filed 2026-05-11 | $53.21M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-03-31 | $1.13M 10-Q · filed 2026-05-11 | $21.99M derived: sum of 2 quarters · filed 2026-05-11 | $41.82M derived: sum of 3 quarters · filed 2026-05-11 | $57.68M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $20.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $40.69M derived: sum of 2 quarters · filed 2026-02-24 | $56.54M derived: sum of 3 quarters · filed 2026-02-24 | $75.12M 10-K · filed 2026-02-24 |
| 2024-09-30 | $19.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $35.68M derived: sum of 2 quarters · filed 2025-11-06 | $54.26M 10-Q · filed 2025-11-06 | $64.70M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $15.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $34.43M 10-Q · filed 2025-08-07 | $44.87M derived: sum of 3 quarters · filed 2026-02-24 | $56.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $18.58M 10-Q · filed 2025-05-08 | $29.01M derived: sum of 2 quarters · filed 2026-02-24 | $40.24M derived: sum of 3 quarters · filed 2026-02-24 | $72.42M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $10.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $21.66M derived: sum of 2 quarters · filed 2026-02-24 | $53.85M derived: sum of 3 quarters · filed 2026-02-24 | $45.93M 10-K · filed 2026-02-24 |
| 2023-09-30 | $11.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $43.41M derived: sum of 2 quarters · filed 2024-11-04 | $35.49M 10-Q · filed 2024-11-04 | $54.53M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $32.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $24.27M 10-Q · filed 2024-08-06 | $43.31M derived: sum of 3 quarters · filed 2025-02-27 | $40.02M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$7.92M 10-Q · filed 2024-05-07 | $11.13M derived: sum of 2 quarters · filed 2025-02-27 | $7.84M derived: sum of 3 quarters · filed 2025-02-27 | $6.05M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $19.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $15.75M derived: sum of 2 quarters · filed 2025-02-27 | $13.96M derived: sum of 3 quarters · filed 2025-02-27 | $22.71M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$3.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$5.08M derived: sum of 2 quarters · filed 2023-11-02 | $3.67M 10-Q · filed 2023-11-02 | $6.73M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $6.96M 10-Q · filed 2023-08-03 | $10.02M derived: sum of 3 quarters · filed 2024-02-20 | $16.01M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $8.75M 10-Q · filed 2023-05-04 | $11.81M derived: sum of 2 quarters · filed 2024-02-20 | $17.80M derived: sum of 3 quarters · filed 2024-02-20 | $16.06M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $9.05M derived: sum of 2 quarters · filed 2024-02-20 | $7.31M derived: sum of 3 quarters · filed 2024-02-20 | $37.39M 10-K · filed 2024-02-20 |
| 2021-09-30 | $5.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $4.26M derived: sum of 2 quarters · filed 2022-11-08 | $34.33M 10-Q · filed 2022-11-08 | $22.80M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $28.34M 10-Q · filed 2022-08-09 | $16.81M derived: sum of 3 quarters · filed 2023-02-21 | $24.59M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $30.07M 10-Q · filed 2022-05-10 | $18.55M derived: sum of 2 quarters · filed 2023-02-21 | $26.32M derived: sum of 3 quarters · filed 2023-02-21 | $8.93M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | -$11.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$3.75M derived: sum of 2 quarters · filed 2023-02-21 | -$21.14M derived: sum of 3 quarters · filed 2023-02-21 | $5.47M 10-K · filed 2023-02-21 |
| 2020-09-30 | $7.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$9.62M derived: sum of 2 quarters · filed 2021-11-10 | $16.99M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$17.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $9.22M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $26.61M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $1.80M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |